- Autolus Therapeutics Reports Full Year 2023 Financial Results and Business Updates
- Autolus Therapeutics receives Medicines and Healthcare products Regulatory Agency (MHRA) certification for Nucleus commercial manufacturing site
- Autolus Therapeutics announces publication in Blood Cancer Journal
- Autolus Therapeutics to Report Full Year 2023 Financial Results and Business Updates on March 14, 2024
- Autolus Therapeutics announces publication in Nature Communications
- Autolus Announces Pricing of Underwritten Offering
- BioNTech and Autolus Announce Strategic CAR-T Cell Therapy Collaboration to Advance Pipeline and Expand Late-Stage Programs
- Autolus Therapeutics announces publication in ACS Chemical Biology
- Autolus Therapeutics announces acceptance of Biologics License Application for obecabtagene autoleucel (obe-cel) as a potential treatment for relapsed/refractory Adult B-cell Acute Lymphoblastic Leukemia (ALL)
- Autolus Therapeutics announces the appointment of Robert W. Azelby to its Board of Directors
More ▼
Key statistics
On Thursday, Autolus Therapeutics PLC (AUTL:NSQ) closed at 6.38, -14.36% below its 52-week high of 7.45, set on Jan 12, 2024.
52-week range
Open | 6.24 |
---|---|
High | 6.44 |
Low | 6.19 |
Bid | 6.20 |
Offer | 6.35 |
Previous close | 6.24 |
Average volume | 1.00m |
---|---|
Shares outstanding | 265.93m |
Free float | 8.82m |
P/E (TTM) | -- |
Market cap | 1.66bn USD |
EPS (TTM) | -1.20 USD |
Data delayed at least 15 minutes, as of Mar 28 2024 20:00 BST.
More ▼